Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
Updates on non-metastatic castration-resistant prostate cancer

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.18
Views: 2397

Prof Kurt Miller, Prof Silke Gillessen, Prof Heather Payne and Dr Eric Small

Professor Kurt Miller chairs a discussion with Professor Silke Gillessen, Professor Heather Payne and Dr Eric Small on the latest data presented at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco, with a focus on the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).

Conversations focused around the SPARTAN data presented at the conference and the positive results from this trial.

The group discuss their opinions around M0 patients receiving certain treatments earlier in the patient pathway, something they feel is supported by PFS2 results from SPARTAN as well as data from STAMPEDE for this patient population.

The effect PSMA PET scans has had on clinical practice is also discussed.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation